Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.51 |
| ▸ | TXN | P10599 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Aminoguanine SCHEMBL21761 | 0.85 | PNP (1.00) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL5181913 | 0.85 | PNP (0.48) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL2051361 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL20577 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL843932 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL22883 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL844207 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL9116 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL6686388 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 | |
| SCHEMBL42760 | 0.76 | PNP (0.73) | PNPMAPTKDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH | 2025-09-25 | — | — | US | claimed |
| CN-119016735-A | Gold nanocluster aggregate with multiple stimulus responsivity and preparation method and application thereof | 中国科学院苏州纳米技术与纳米仿生研究所 | 2024-11-26 | — | — | CN | claimed |
| WO-2023215819-A2 | ANTIPARASITIC AGENTS AND METHODS | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-11-09 | — | — | WO | claimed |
| WO-2022160323-A1 | APPLICATION OF NUCLEOSIDE ANALOGUE IN PREPARATION OF DRUGS FOR PREVENTING OR TREATING GASTROINTESTINAL DISEASES | 兰州大学 | 2022-08-04 | — | — | WO | claimed |
| US-20220098262-A1 | ANTIBODY-TUMOR NECROSIS FACTOR alpha FUSION PROTEIN AND ITS PREPARATION AND APPLICATIONS | DING, Bang (CN) | 2022-03-31 | — | — | US | claimed |
| CN-107603976-B | Methods and compositions for RNA-directed target DNA modification and transcriptional regulation | 埃玛纽埃尔·沙尔庞捷 | 2021-10-12 | — | — | CN | claimed |
| CN-112707921-A | Synthesis of fluorescence label of enzyme inhibitor | 南京碳硅人工智能生物医药技术研究院有限公司 | 2021-04-27 | — | — | CN | claimed |
| WO-2020233723-A1 | QUINOLINE DERIVATIVES FOR TREATMENT OF HEAD AND NECK CANCER | 正大天晴药业集团股份有限公司 (CN) | 2020-11-26 | — | — | WO | claimed |
| WO-2020118605-A1 | ANTIBODY-TUMOR NECROSIS FACTOR-α FUSION PROTEIN, PREPARATION METHOD THEREFOR AND USES THEREOF | 丁邦 | 2020-06-18 | — | — | WO | claimed |
| CN-109422652-A | Application of the salicylic derivative of chloroethene acyloxy in drug | 南京大学 | 2019-03-05 | — | — | CN | claimed |
| EP-1583842-A4 | METHODS FOR THE ELECTROCHEMICAL DETECTION OF MULTIPLE TARGET COMPOUNDS | UNIV NORTH CAROLINA (US) | 2007-07-04 | — | — | EP | claimed |
| EP-1583842-A2 | METHODS FOR THE ELECTROCHEMICAL DETECTION OF MULTIPLE TARGET COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-10-12 | — | — | EP | claimed |
| WO-2003089895-A2 | METHODS FOR THE ELECTROCHEMICAL DETECTION OF MULTIPLE TARGET COMPOUNDS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-10-30 | — | — | WO | claimed |
| US-6638494-B1 | Iron hydroxide, ferric hydrate, iron oxide, iron mixed oxide or iron; di- or polycarboxylic acid stabilizer; aggregation prevention; antitumor and contrast agents; immune boosters, magnetic resonance imaging, cell fusion, gene transfer | PILGRIMM HERBERT (DE) | 2003-10-28 | — | — | US | claimed |
| EP-0888545-B1 | SUPER-PARAMAGNETIC PARTICLES WITH INCREASED R 1 RELAXIVITY, PROCESSES FOR PRODUCING SAID PARTICLES AND USE THEREOF | PILGRIMM HERBERT (DE) | 2002-01-23 | — | — | EP | claimed |
| US-6242428-B1 | NUCLEOSIDES AND NUCLEOSIDE DIMERS CONTAINING AN L-SUGAR IN AT LEAST ONE OF THE NUCLEOSIDES | UNISEARCH LIMITED (AU) | 2001-06-05 | — | — | US | claimed |
| EP-1069903-A1 | NOVEL NUCLEOSIDE ANALOGS AND USES IN TREATING DISEASE | Lipitek International, Inc. (US) | 2001-01-24 | — | — | EP | claimed |
| WO-1999045935-A1 | NOVEL NUCLEOSIDE ANALOGS AND USES IN TREATING DISEASE | LIPITEK INTERNATIONAL, INC. (US) | 1999-09-16 | — | — | WO | claimed |
| US-5744600-A | VIRICIDES, ANTITUMOR AGENTS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1998-04-28 | — | — | US | claimed |
| EP-0689430-B1 | SUPERPARAMAGNETIC PARTICLES, PROCESS FOR PRODUCING THE SAME AND THEIR USE | SILICA GEL GMBH (DE) | 1997-08-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250295658-A1 | ANTIPARASITIC AGENTS AND METHODS | DHFR, DHODH, MTHFD1 | PNP 29/4885MAPT 3840/4885KDM4E 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.